Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Inozyme Pharma Inc (INZY)

Inozyme Pharma Inc (INZY)
0.8103 x 24 0.9000 x 5
Pre-market by (Cboe BZX)
0.8861 +0.0054 (+0.61%) 04/11/25 [NASDAQ]
0.8103 x 24 0.9000 x 5
Pre-market 0.8861 unch (unch) 07:01 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8319
Day High
0.9015
Open 0.8800
Previous Close 0.8807 0.8807
Volume 513,300 513,300
Avg Vol 470,835 470,835
Stochastic %K 53.28% 53.28%
Weighted Alpha -79.52 -79.52
5-Day Change +0.0649 (+7.90%) +0.0649 (+7.90%)
52-Week Range 0.7200 - 6.2400 0.7200 - 6.2400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,923
  • Shares Outstanding, K 64,240
  • Annual Sales, $ 0 K
  • Annual Income, $ -102,020 K
  • EBIT $ -104 M
  • EBITDA $ -108 M
  • 60-Month Beta 1.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.98
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.63
  • Most Recent Earnings $-0.42 on 03/10/25
  • Next Earnings Date 05/06/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 467.26% ( -319.84%)
  • Historical Volatility 78.99%
  • IV Percentile 97%
  • IV Rank 57.35%
  • IV High 787.10% on 04/04/25
  • IV Low 37.16% on 05/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 4,573
  • Open Int (30-Day) 4,712

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.43
  • Number of Estimates 6
  • High Estimate -0.40
  • Low Estimate -0.47
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -13.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7200 +23.07%
on 04/07/25
Period Open: 1.0600
1.1000 -19.45%
on 03/12/25
-0.1739 (-16.41%)
since 03/11/25
3-Month
0.7200 +23.07%
on 04/07/25
Period Open: 1.9950
2.0830 -57.46%
on 01/13/25
-1.1089 (-55.58%)
since 01/10/25
52-Week
0.7200 +23.07%
on 04/07/25
Period Open: 5.2200
6.2400 -85.80%
on 09/17/24
-4.3339 (-83.02%)
since 04/11/24

Most Recent Stories

More News
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

INZY : 0.8861 (+0.61%)
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

INZY : 0.8861 (+0.61%)
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

INZY : 0.8861 (+0.61%)
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

INZY : 0.8861 (+0.61%)
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

INZY : 0.8861 (+0.61%)
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

INZY : 0.8861 (+0.61%)
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

INZY : 0.8861 (+0.61%)
Inozyme Pharma to Present at Upcoming Investor Conferences

INZY : 0.8861 (+0.61%)
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

INZY : 0.8861 (+0.61%)
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

INZY : 0.8861 (+0.61%)

Business Summary

Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston,...

See More

Key Turning Points

3rd Resistance Point 0.9840
2nd Resistance Point 0.9428
1st Resistance Point 0.9144
Last Price 0.8861
1st Support Level 0.8448
2nd Support Level 0.8036
3rd Support Level 0.7752

See More

52-Week High 6.2400
Fibonacci 61.8% 4.1314
Fibonacci 50% 3.4800
Fibonacci 38.2% 2.8286
Last Price 0.8861
52-Week Low 0.7200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar